Götz Thomalla,Florent Boutitie,Henry Ma,Masatoshi Koga,Peter Ringleb,Lee H Schwamm,Ona Wu,Martin Bendszus,Christopher F Bladin,Bruce C V Campbell,Bastian Cheng,Leonid Churilov,Martin Ebinger,Matthias Endres,Jochen B Fiebach,Mayumi Fukuda-Doi,Manabu Inoue,Timothy J Kleinig,Lawrence L Latour,Robin Lemmens,Christopher R Levi,Didier Leys,Kaori Miwa,Carlos A Molina,Keith W Muir,Norbert Nighoghossian,Mark W Parsons,Salvador Pedraza,Peter D Schellinger,Stefan Schwab,Claus Z Simonsen,Shlee S Song,Vincent Thijs,Danilo Toni,Chung Y Hsu,Nils Wahlgren,Haruko Yamamoto,Nawaf Yassi,Sohei Yoshimura,Steven Warach,Werner Hacke,Kazunori Toyoda,Geoffrey A Donnan,Stephen M Davis,Christian Gerloff,Evaluation of unknown Onset Stroke thrombolysis trials (EOS) investigators

Abstract:Background: Patients who have had a stroke with unknown time of onset have been previously excluded from thrombolysis. We aimed to establish whether intravenous alteplase is safe and effective in such patients when salvageable tissue has been identified with imaging biomarkers. Methods: We did a systematic review and meta-analysis of individual patient data for trials published before Sept 21, 2020. Randomised trials of intravenous alteplase versus standard of care or placebo in adults with stroke with unknown time of onset with perfusion-diffusion MRI, perfusion CT, or MRI with diffusion weighted imaging-fluid attenuated inversion recovery (DWI-FLAIR) mismatch were eligible. The primary outcome was favourable functional outcome (score of 0-1 on the modified Rankin Scale [mRS]) at 90 days indicating no disability using an unconditional mixed-effect logistic-regression model fitted to estimate the treatment effect. Secondary outcomes were mRS shift towards a better functional outcome and independent outcome (mRS 0-2) at 90 days. Safety outcomes included death, severe disability or death (mRS score 4-6), and symptomatic intracranial haemorrhage. This study is registered with PROSPERO, CRD42020166903. Findings: Of 249 identified abstracts, four trials met our eligibility criteria for inclusion: WAKE-UP, EXTEND, THAWS, and ECASS-4. The four trials provided individual patient data for 843 individuals, of whom 429 (51%) were assigned to alteplase and 414 (49%) to placebo or standard care. A favourable outcome occurred in 199 (47%) of 420 patients with alteplase and in 160 (39%) of 409 patients among controls (adjusted odds ratio [OR] 1·49 [95% CI 1·10-2·03]; p=0·011), with low heterogeneity across studies (I2=27%). Alteplase was associated with a significant shift towards better functional outcome (adjusted common OR 1·38 [95% CI 1·05-1·80]; p=0·019), and a higher odds of independent outcome (adjusted OR 1·50 [1·06-2·12]; p=0·022). In the alteplase group, 90 (21%) patients were severely disabled or died (mRS score 4-6), compared with 102 (25%) patients in the control group (adjusted OR 0·76 [0·52-1·11]; p=0·15). 27 (6%) patients died in the alteplase group and 14 (3%) patients died among controls (adjusted OR 2·06 [1·03-4·09]; p=0·040). The prevalence of symptomatic intracranial haemorrhage was higher in the alteplase group than among controls (11 [3%] vs two [<1%], adjusted OR 5·58 [1·22-25·50]; p=0·024). Interpretation: In patients who have had a stroke with unknown time of onset with a DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outcome at 90 days than placebo or standard care. A net benefit was observed for all functional outcomes despite an increased risk of symptomatic intracranial haemorrhage. Although there were more deaths with alteplase than placebo, there were fewer cases of severe disability or death. Funding: None.

Intravenous Thrombolysis in Patients With White Matter Hyperintensities in the WAKE-UP Trial

Microbleeds, Cerebral Hemorrhage, and Functional Outcome After Stroke Thrombolysis.

Relationship Between White-Matter Hyperintensities and Hematoma Volume and Growth in Patients with Intracerebral Hemorrhage

Global White Matter Hypoperfusion on CT Predicts Larger Infarcts and Hemorrhagic Transformation after Acute Ischemia.

Endovascular Thrombectomy with or Without Intravenous Alteplase in Acute Stroke

Abstract W P43: Extent of “blooming Effect” Predicts Middle Cerebral Artery Recanalization after Intravenous Thrombolysis

The Relationship Between T2 White-Matter Hyperintensities and Hemorrhagic Transformation and Neurological Outcome after Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke

Serious Adverse Events and Their Impact on Functional Outcome in Acute Ischemic Stroke in the WAKE-UP Trial

Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data

Abstract WP16: Thrombolysis in Wake-Up Stroke Improves Outcomes, Reduces Cost, and Reverses ADC Lesions

Abstract WP186: The Burden of White Matter Hyperintensities on Function Outcomes in Patients Treated for Acute Ischemic Stroke: A Post-Hoc Analysis of the IMS-III Trial

The efficacy of intravenous thrombolysis in acute ischemic stroke patients with white matter hyperintensity

Thrombolysis for Wake-Up Stroke Versus Non–Wake-Up Unwitnessed Stroke: EOS Individual Patient Data Meta-Analysis

Author Response: Cerebral Microbleeds and Treatment Effect of Intravenous Thrombolysis in Acute Stroke: An Analysis of the WAKE-UP Randomized Clinical Trial

Abstract WMP11: Intravenous Thrombolysis in Patients Without versus With Visible Occlusion: A Secondary Analysis From the AcT Trial

More extensive white matter hyperintensity is linked with higher risk of remote intracerebral hemorrhage after intravenous thrombolysis

Blood-brain barrier leakage in the penumbra is associated with infarction on follow-up imaging in acute ischemic stroke

Cerebral computed tomography-graded white matter lesions are associated with worse outcome after thrombolysis in patients with stroke

Effectiveness and Predictors of Poor Prognosis Following Intravenous Thrombolysis in Patients with Wake-Up Ischemic Stroke Guided by Rapid MRI

Excessive White Matter Hyperintensity Increases Susceptibility to Poor Functional Outcomes After Acute Ischemic Stroke

Haemorrhage after thrombectomy with adjuvant thrombolysis in unknown onset stroke depends on high early lesion water uptake